...
首页> 外文期刊>American journal of medical genetics, Part A >Mucopolysaccharidosis type VI: A predominantly cardiac phenotype associated with homozygosity for p.R152W mutation in the ARSB gene
【24h】

Mucopolysaccharidosis type VI: A predominantly cardiac phenotype associated with homozygosity for p.R152W mutation in the ARSB gene

机译:VI型粘多糖贮积病:一种主要的心脏表型,与ARSB基因中p.R152W突变的纯合性相关

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Mucopolysaccharidosis type VI (MPS VI) is a rare lysosomal, autosomal recessive storage disorder caused by deficient activity of N-acetylgalactosamine-4-sulfatase (ARSB). Approximately, 140 ARSB gene mutations have been identified; however, most are private mutations making genotype-phenotype correlation for most MPS VI patients difficult. The aim of this study was to describe the natural clinical course in patients homozygous for the p.R152W mutation from eight unrelated families. From our database of 70 patients with MPS VI, we selected 10 patients homozygous for the p.R152W mutant allele (median age 27.5 years, range 18-38 years). We performed a cross-sectional observational study characterizing the onset and prevalence of clinical manifestations. First signs of the disease, such as cardiac valve disease, slightly decreased joint range of motion and mild growth retardation, were observed in mid-adolescent years (median 15 years). Within the disease course, the most common clinical feature in all the patients was progressive heart disease of predominantly valve origin leading to symptoms of heart failure. Other typical MPS VI features were subtle and not present in all the patients. Delays up to 23 years (median 8.5 years) intervened between symptom onset and disease diagnosis. Patients homozygous for the p.R152W mutation present a cardiac variant of MPS VI characterized by progressive cardiac valve disease leading to serious cardiac complications including abrupt death due to cardiac failure.
机译:VI型粘多糖贮积病(MPS VI)是一种罕见的溶酶体,常染色体隐性存储障碍,由N-乙酰半乳糖胺-4-硫酸酯酶(ARSB)活性不足引起。已鉴定出约140种ARSB基因突变。然而,大多数是私人突变,使得大多数MPS VI患者的基因型与表型相关性变得困难。这项研究的目的是描述来自八个无关家庭的p.R152W突变纯合患者的自然临床过程。从我们的70例MPS VI患者数据库中,我们选择了10例纯合p.R152W突变体等位基因的患者(中位年龄27.5岁,范围18-38岁)。我们进行了一项横断面观察研究,以表征临床表现的发病率和患病率。在青少年中期(中位年龄为15岁)观察到该疾病的最初体征,例如心脏瓣膜疾病,关节活动范围略有减少和轻度发育迟缓。在疾病过程中,所有患者中最常见的临床特征是主要是瓣膜起源的进行性心脏病,导致心力衰竭症状。 MPS VI的其他典型特征是微妙的,并非在所有患者中都存在。症状发作与疾病诊断之间的延迟时间最长可达23年(中位数8.5年)。 p.R152W突变纯合的患者表现出MPS VI的心脏变异,其特征是进行性心脏瓣膜疾病导致严重的心脏并发症,包括由于心力衰竭而突然死亡。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号